RxDoctor Payments Data

Michael Fennell, PA

Physician Assistant · Orchard Park, NYNPI 1023765708

Payments from drug & device makers

$3,485in general payments, 2019–2025

Across 115 payments — averaging $30.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$884
  • UCB, Inc.$274
  • Aurinia Pharma U.S., Inc.$219
  • Novartis$185
  • GSK$180
  • plus $582 from 12 others

What the payments were for

  • Food & beverage$3,476100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,485 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$22,532
Medicare patients
128
Services billed
1,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab20$294,020
Enbrel SureclickEtanercept30$251,485
Xeljanz XrTofacitinib Citrate15$85,558
OtezlaApremilast11$53,143
Adalimumab-Adaz(Cf) PenAdalimumab-Adaz12$15,328
Hydroxychloroquine Sulfate122$4,313
MethotrexateMethotrexate Sodium143$3,356
Leflunomide33$1,777
Diclofenac Sodium36$1,412
Celecoxib29$1,041
Colchicine36$999
Duloxetine Hcl46$807
Gabapentin52$705
Prednisone84$589
Folic Acid43$542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,161$53,14311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Orchard Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →